Combining Clinical, Biological, and Morphological Data from European Cohorts to Improve Risk Prediction in Venous Thromboembolism as Part of the MORPHEUS Project

What this Trial Is About

The MORPHEUS project is an international research program involving eight European countries, coordinated by France, that aims to improve long-term treatment for unprovoked venous thromboembolic disease VTED. This research combines clinical, biological, morphological, and socio-anthropological data to create a risk prediction tool to support shared medical decision-making. The MC-MORPHEUS phase focuses on identifying key biomarkers predictive of risks like thromboembolic recurrence, bleeding, and mortality. MC-MORPHEUS collects and merges data from 14 European cohorts into a single database, integrating clinical, biological, and morphological information from patients with venous thromboembolism who have been followed for months or years. This combined dataset will enhance the identification of important biomarkers, which will be used to develop and validate a time-dependent, multi-level risk prediction tool in future studies. Participants in these cohorts have been monitored over long periods, and the study involves processing and analyzing this merged data from late 2024 through 2025. The research will assess consistency between merged and original cohort data and evaluate long-term risks of thromboembolic recurrence, bleeding, and death over 20 years. This observational study does not involve direct interventions but focuses on data analysis and tool development to improve VTED treatment.

CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".